Glycosylation differences of an anti-VEGF monoclonal antibody (PRO-169) and its extensive comparison with Bevacizumab

PRO-169 is an anti-VEGF monoclonal antibody developed by Laboratorios Sophia that shares its sequence with Bevacizumab (BVZ); though, PRO-169 is intended for intravitreal administration. In this study, analytical characterization showed that PRO-169 had glycosylation differences in comparison to BVZ...

Full description

Saved in:
Bibliographic Details
Published in:Biologicals 2023-11, Vol.84, p.101711-101711, Article 101711
Main Authors: Quiñonez-Alvarado, Mayra G., Chávez-Hurtado, Paulina, Caro-Palomera, Jesús C., Niño-Trejo, Oriana L., Jiménez-Dolores, José I., Muñoz-Villegas, Patricia, Baiza-Durán, Leopoldo, Quintana-Hau, Juan D.
Format: Article
Language:English
Subjects:
Biological activity
Cytotoxicity
Glycosylation
Immunogenicity
Intravitreal injection
Monoclonal antibody
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PRO-169 is an anti-VEGF monoclonal antibody developed by Laboratorios Sophia that shares its sequence with Bevacizumab (BVZ); though, PRO-169 is intended for intravitreal administration. In this study, analytical characterization showed that PRO-169 had glycosylation differences in comparison to BVZ reference product (RP); since it had more content of G1F, G2F, sialic acid and high mannose. Further investigation was performed to evaluate if differences between both products would affect the efficacy and safety profile of PRO-169. PRO-169 had no alteration in its in vitro biological activity; moreover, no cytotoxicity or immunogenicity concerns should be expected as demonstrated by different orthogonal methods at analytical, in vitro and in vivo assays. These results support moving to the clinical testing of PRO-169 since no major complications will be expected with its clinical use for the treatment of ophthalmic diseases.
ISSN:1045-1056
1095-8320
DOI:10.1016/j.biologicals.2023.101711